Zealand Pharma 以 1 亿美元出售其持有的 Takeda 血液肿瘤药物 rusfertide 权益，FDA 审批在即
Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decision
Zealand Pharma 以 1 亿美元出售其持有的血液肿瘤药物 rusfertide 权益。该药由 Takeda 与 Protagonist Therapeutics 合作开发，FDA 正在审评其上市批准。
发生了什么
Zealand Pharma has sold its economic rights to rusfertide for USD 100 million. Company disclosure shows this was a royalty purchase and sale agreement with Royalty Pharma dated August 12, 2026. The article places the transaction ahead of the FDA approval decision, and peer-reviewed coverage confirms the FDA had approved rusfertide (brand name Mimrylo) for adult polycythemia vera patients as of September 16, 2026. Rusfertide is co-developed by Takeda and Protagonist Therapeutics under a January 31, 2024 license agreement, supported by positive Phase 3 VERIFY topline results announced in March 2025.
为什么重要
The transaction converted Zealand's future, approval-dependent royalty stream into immediate cash ahead of the regulatory verdict. For Royalty Pharma, committing USD 100 million before approval reflects a bet that rusfertide would clear the FDA and capture meaningful share in polycythemia vera, an indication that reportedly secured FDA priority review. Because the deal was structured as a royalty sale rather than an outright asset transfer, Zealand likely retains certain milestone or royalty entitlements under the original Collaboration Agreement referenced in SEC filings, though the specific carve-out is not detailed in the reviewed materials.
还缺什么
The detailed economic split between what Zealand sold and what it retained, and which milestones remain with Zealand, are not disclosed in the provided materials. Post-approval commercial uptake of Mimrylo will determine whether the USD 100 million price proved favorable for Royalty Pharma. Zealand's intended use of the proceeds and the specific arbitration-related payment referenced in the SEC filing are not addressed in the reviewed materials.
来源：文献与产业新闻 · fiercebiotech.com